印度的Wockhardt制药公司获得美国林业发展局关于新型抗生素WCK 6777的快车道指认,以治疗复杂的感染。 Indian pharmaceutical firm Wockhardt receives Fast Track designation for novel antibiotic WCK 6777 from US FDA to treat complex infections.
印度制药公司 Wockhardt Limited 的新型抗生素 WCK 6777 已获得美国 FDA 的快速通道指定，该抗生素旨在治疗复杂的尿路和腹腔内感染。 Wockhardt Limited, an Indian pharmaceutical company, has received Fast Track designation from the US FDA for its novel antibiotic WCK 6777, aimed at treating complicated urinary tract and intra-abdominal infections. 这种每天服用一次的β- 乳酸增强剂向多药耐药的阴性细菌,并在I期研究中显示出有前途的安全性. This once-daily β-lactam enhancer targets multi-drug-resistant Gram-negative bacteria and has shown a promising safety profile in a Phase I study. 该公司还在开发额外的抗生素,以抗药性感染。 The company is also developing additional antibiotics to combat drug-resistant infections.